Daum R S, Glode M P, Ambrosino D, Halsey N, Goldmann D A, Mather F J, Russell R, Kamon J, Murray M, Band J D
Antimicrob Agents Chemother. 1983 Nov;24(5):658-62. doi: 10.1128/AAC.24.5.658.
We compared the effectiveness of rifampin-trimethoprim in fixed combination (3.75:1) to rifampin alone in the eradication of Haemophilus influenzae type b carriage among contacts of patients with invasive infection caused by this organism. The study population was composed of 127 index patients and 620 contacts. Twenty-six percent of contacts were colonized. Rifampin-trimethoprim eradicated carriage in 77.6% of contacts (71.1% in contacts less than 5 years, 84.2% in contacts greater than or equal to 5 years) whereas rifampin eradicated carriage in 69.9% of contacts (56.4% in contacts less than 5 years, 81.8% in contacts greater than or equal to 5 years). A single isolate resistant to rifampin and rifampin-trimethoprim was encountered. The eradication rate achieved with this regimen of rifampin-trimethoprim was too low to recommend its routine use. However, a higher dose or longer course might merit clinical trial.
我们比较了固定剂量联合使用的利福平-甲氧苄啶(3.75:1)与单独使用利福平在清除由b型流感嗜血杆菌引起的侵袭性感染患者的接触者中该菌携带情况方面的有效性。研究人群包括127名索引患者和620名接触者。26%的接触者被定植。利福平-甲氧苄啶使77.6%的接触者清除了携带情况(5岁以下接触者中为71.1%,5岁及以上接触者中为84.2%),而利福平使69.9%的接触者清除了携带情况(5岁以下接触者中为56.4%,5岁及以上接触者中为81.8%)。遇到了1株对利福平和利福平-甲氧苄啶耐药的分离株。这种利福平-甲氧苄啶方案的清除率过低,不建议常规使用。然而,更高剂量或更长疗程可能值得进行临床试验。